Corient Private Wealth
TFFP

Corient Private Wealth’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History

Corient Private Wealth’s Portfolio TFFP Stock Details TFFP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-760
Closed -$6.65K – 2363
2023
Q3 		$6.65K Hold
760
– – ﹤0.01% 2126
2023
Q2 		$8.93K Hold
760
– – ﹤0.01% 2065
2023
Q1 		$13K Buy
760
+280
+58% +$6.07K ﹤0.01% 1985
2022
Q4 		$12.6K Buy
+480
New +$22.8K ﹤0.01% 1677

Other funds holding TFFP

CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Corient Private Wealth's TFFP Position: Q4 2023 in Review

Corient Private Wealth sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2023, closing a stake of 760 shares — an estimated $6.65K sold.

Corient Private Wealth first reported a position in TFFP in Q4 2022 and held it in 4 quarters. The position peaked at $13K in Q1 2023. 23 funds tracked by Wall St. Rank hold TFFP as of Q4 2023.

  • Corient Private Wealth reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Corient Private Wealth sold 760 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $6.65K.
  • Corient Private Wealth first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Corient Private Wealth's TFF Pharmaceuticals, Inc. Common Stock position peaked at $13K in Q1 2023.
  • 23 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Corient Private Wealth's 13F filing for Q4 2023, filed 9 Feb 2024.